Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

被引：19

作者：

Parsons, H. A. ^{[1
,2
,3
,17
]}

Blewett, T. ^{[4
]}

Chu, X. ^{[5
]}

Sridhar, S. ^{[4
]}

Santos, K. ^{[1
]}

Xiong, K. ^{[4
]}

Abramson, V. G. ^{[6
]}

Patel, A. ^{[1
]}

Cheng, J. ^{[4
]}

Brufsky, A. ^{[7
]}

Rhoades, J. ^{[4
]}

Force, J. ^{[8
]}

Liu, R. ^{[4
]}

Traina, T. A. ^{[9
]}

Carey, L. A. ^{[10
]}

Rimawi, M. F. ^{[11
]}

Miller, K. D. ^{[12
]}

Stearns, V. ^{[13
]}

Specht, J. ^{[14
]}

Falkson, C. ^{[15
,20
]}

Burstein, H. J. ^{[1
,2
,3
]}

Wolff, A. C.

Winer, E. P. ^{[1
,2
,19
]}

Tayob, N. ^{[5
]}

Krop, I. E. ^{[1
,2
,3
,19
]}

Markrigiorgos, G. M. ^{[16
]}

Golub, T. R. ^{[4
]}

Mayer, E. L. ^{[1
,2
,3
,17
]}

Adalsteinsson, V. A. ^{[4
,18
]}

机构：

[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Broad Inst MIT & Harvard, Cambridge, MA USA

[5] Dana Farber Canc Inst, Data Sci, Boston, MA USA

[6] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[7] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA

[8] Duke Canc Ctr, Durham, NC USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[11] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX USA

[12] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[13] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[14] Seattle Canc Care Alliance, Seattle, WA USA

[15] Univ Alabama Birmingham, Birmingham, AL USA

[16] Dana Farber Canc Inst, Radiat Oncol, Boston, MA USA

[17] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA

[18] Dana Farber Canc Inst, 75 Ames St, Cambridge, MA 02142 USA

[19] Yale Canc Ctr, New Haven, CT USA

[20] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷 / 10期

关键词：

circulating tumor DNA; triple-negative breast cancer; biomarkers; recurrence; minimal residual disease; SURVIVAL; RISK;

D O I：

10.1016/j.annonc.2023.08.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: We aimed to examine circulating tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive assay in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy.Patients and methods: We identified responders (RCB 0/1) and matched non-responders (RCB 2/3) from the phase II TBCRC 030 prospective study of neoadjuvant paclitaxel versus cisplatin in TNBC. We collected plasma samples at baseline, 3 weeks and 12 weeks (end of therapy). We created personalized ctDNA assays utilizing MAESTRO mutation enrichment sequencing. We explored associations between ctDNA and RCB status and disease recurrence.Results: Of 139 patients, 68 had complete samples and no additional neoadjuvant chemotherapy. Twenty-two were responders and 19 of those had sufficient tissue for whole-genome sequencing. We identified an additional 19 nonresponders for a matched case-control analysis of 38 patients using a MAESTRO ctDNA assay tracking 319-1000 variants (median 1000 variants) to 114 plasma samples from 3 timepoints. Overall, ctDNA positivity was 100% at baseline, 79% at week 3 and 55% at week 12. Median tumor fraction (TFx) was 3.7 x 10(4) (range 7.9 x 10(-7)-4.9 x 10(1)). TFx decreased 285-fold from baseline to week 3 in responders and 24-fold in non-responders. Week 12 ctDNA clearance correlated with RCB: clearance was observed in 10 of 11 patients with RCB 0, 3 of 8 with RCB 1, 4 of 15 with RCB 2 and 0 of 4 with RCB 3. Among six patients with known recurrence, five had persistent ctDNA at week 12.Conclusions: Neoadjuvant chemotherapy for TNBC reduced ctDNA TFx by 285-fold in responders and 24-fold in nonresponders. In 58% (22/38) of patients, ctDNA TFx dropped below the detection level of a commercially available test, emphasizing the need for sensitive tests. Additional studies will determine whether ctDNA-guided approaches can improve outcomes.

引用

页码：899 / 906

页数：8

共 50 条

[41] Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer
Zivanovic Bujak, Andjelija
Dawson, Sarah-Jane
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06) : 523 - 524
[42] Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions
Saliou, Adrien
Bidard, Francois-Clement
Lantz, Olivier
Stern, Marc-Henri
Vincent-Salomon, Anne
Proudhon, Charlotte
Pierga, Jean-Yves
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (01) : 39 - 50
[43] Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer
Shang, Mao
Chang, Chunxiao
Pei, Yanqing
Guan, Yin
Chang, Jin
Li, HuiHui
JOURNAL OF CANCER, 2018, 9 (24): : 4627 - 4634
[44] Neoadjuvant Chemotherapy and Neoadjuvant Chemotherapy With Immunotherapy Result in Different Tumor Shrinkage Patterns in Triple-Negative Breast Cancer
Zou, Jiachen
Zhang, Liulu
Chen, Yuanqi
Lin, Yingyi
Cheng, Minyi
Zheng, Xingxing
Zhuang, Xiaosheng
Wang, Kun
JOURNAL OF BREAST CANCER, 2024, 27 (01) : 27 - 36
[45] Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy? Reply
Mayer, Ingrid A.
Zhao, Fengmin
Arteaga, Carlos L.
Symmans, William F.
Park, Ben H.
Burnette, Brian L.
Tevaarwerk, Amye J.
Garcia, Sofia F.
Smith, Karen L.
Makower, Della F.
Block, Margaret
Morley, Kimberly A.
Jani, Chirag R.
Mescher, Craig
Dewani, Shabana J.
Tawfik, Bernard
Flaum, Lisa E.
Mayer, Erica L.
Sikov, William M.
Rodler, Eve T.
Wagner, Lynne I.
DeMichele, Angela M.
Sparano, Joseph A.
Wolff, Antonio C.
Miller, Kathy D.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3522 - +
[46] An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
Blaye, C.
Darbo, E.
Debled, M.
Brouste, V
Velasco, V.
Pinard, C.
Larmonier, N.
Pellegrin, I
Tarricone, A.
Arnedos, M.
Commeny, J.
Bonnefoi, H.
Larmonier, C.
MacGrogan, G.
ESMO OPEN, 2022, 7 (04)
[47] An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
Blaye, C.
Darbo, E.
Debled, M.
Brouste, V.
Velasco, V.
Pinard, C.
Pellegrin, I.
Tarricone, A.
Arnedos, M.
Commeny, J.
Bonnefoi, H.
Larmonier, C.
Macgrogan, G.
ANNALS OF ONCOLOGY, 2022, 33 : S127 - S127
[48] Residual Cancer Burden After Neoadjuvant Chemotherapy in Breast Cancer Patients
Elder, E. A.
Livasy, C.
Donahue, E.
Neelands, B. J.
Patrick, A.
Needham, M.
Sarantou, T.
Hadzikadic-Gusic, L.
White, R.
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S53 - S53
[49] High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.
Oner, Gizem
Onder, Semen
Karatay, Huseyin
Tukenmez, Mustafa
Muslumanoglu, Mahmut
Igci, Abdullah
Dinccag, Ahmet
Ozmen, Vahit
Aydiner, Adnan
Yavuz, Ekrem
Cabioglu, Neslihan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[50] Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple negative breast cancer
Pierga, J-Y.
Riva, F.
Houy, A.
Saliou, A.
Madic, J.
Rampanou, A.
Hego, C.
Milder, M.
Cottu, P.
Sablin, M-P.
Vincent-Salomon, A.
Lantz, O.
Stern, M-H.
Proudhon, C.
Bidard, F-C.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →